الإحصائيات الأساسية
| CIK | 1711786 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hoth Therapeutics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 20, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 22, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated August 22, 2025 (the “Effective Date”), is by and between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and Robb Knie (the “Executive”). WHEREAS, the Company and Executive entered into that certain Employment Agreement, dated March 28, 2023 (the “Prior Employment Agreement”); WHEREAS, the Company |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeut |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No. |
|
| August 5, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Hoth Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, |
|
| August 5, 2025 |
Amendment No. 2 to Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan Exhibit 10.3 AMENDMENT NO. 2 TO HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), hereby amends its Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”) as set forth below, which amendments shall be effective as the date set forth below, but if and only if the Company’s shareholders approve |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 24, 2025 |
Exhibit 99.1 HT - 001 The first therapy for EGFR inhibitor induced cutaneous toxicities Innovating for Everyone Safe Harbor Statement A significant unmet need Cancer patients on EGFR inhibitors experiencing severe dermatological side effects are limited to dose - reduction or stopping treatment entirely Epidermal growth factor receptor inhibitors (EGFRIs) are used in multiple cancer types affectin |
|
| June 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2025 |
Exhibit 99.1 Hoth Therapeutics Regains Nasdaq Compliance – Clears Key Listing Hurdle, Reaffirms Path Toward Growth June 18 2025 – NEW YORK, NY – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq’s minimum bid price requirement. On June 18, 2025, the Company received |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2025 |
Exhibit 99.1 June 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believe,” |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| April 15, 2025 |
Exhibit 99.1 Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): ● Patients experienced a 50% reduction in pruritus severity, with mean scores droppin |
|
| March 28, 2025 |
Description of the Registrant’s Securities EXhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Hoth Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description |
|
| March 28, 2025 |
Amended and Restated Insider Trading Policy Exhibit 19.1 AMENDED & RESTATED Insider Trading POLICY (Effective Date: February 5, 2025) INTRODUCTION & REASONS FOR AN INSIDER TRADING POLICY The Board of Directors (the “Board”) of Hoth Therapeutics Inc. (the “Company”) has adopted this amended & restated insider trading policy (this “Policy”) to promote compliance by Insiders (as defined below) with laws that prohibit certain persons aware of m |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 28, 2025 |
Form of Stock Unit Agreement pursuant to the Hoth Therapeutics, Inc. 2018 Equity Incentive Plan Exhibit 10.34 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK UNIT AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby awards Stock Units to the Participant named below. The terms and conditions of the Award are set forth in this cover sheet, in the attached Stock Unit Agreement and in the Company’s 2018 Equity Incentive Plan (the “Plan”). This cover sheet is incorporated into and a |
|
| March 28, 2025 |
Exhibit 10.35 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby awards a Restricted Stock Grant (the “Restricted Stock”) to the Participant named below. The terms and conditions of the Restricted Stock Grant are set forth in this cover sheet and the attached Restricted Stock Grant Agreement and in the Company’s 2018 E |
|
| March 28, 2025 |
Exhibit 10.32 GRANT NO. HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby grants an Option to purchase Shares to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attached Incentive Stock Option Agreement and in the Company’s 2018 Equity Incentive Plan (the “Pla |
|
| March 28, 2025 |
Exhibit 10.36 HOTH THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE (2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted a Rest |
|
| March 28, 2025 |
Exhibit 10.33 GRANT NO. HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN NONSTATUTORY STOCK OPTION AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby grants an Option to purchase Shares to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attached Nonstatutory Stock Option Agreement and in the Company’s 2018 Equity Incentive Plan (th |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 25, 2025 |
Agreement by and between the Company and OnTargetx R&D Inc. dated March 24, 2025 Exhibit 10.1 CONFIDENTIAL Project Order / Proposal N-0006 24-MAR-2025 OnTargetx R&D Inc. THIS PROJECT ORDER NO. N-0006 is between Hoth Therapeutics (“CLIENT”) and OnTargetx R&D Inc. (“PROVIDER”), which upon execution by both parties, shall be incorporated into and subject to the terms and conditions of the Master Service Agreement between Hoth Therapeutics and PROVIDER. CLIENT hereby engages PROVI |
|
| February 7, 2025 |
Up to $5,000,000 Common Stock Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023 To Prospectus Supplement dated November 8, 2024) Up to $5,000,000 Common Stock Common Stock Hoth Therapeutics, Inc. This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus, dated June 16, 2023, filed as a part of our registratio |
|
| February 7, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 24, 2025 |
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements New York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the “Company” or “Hoth Therapeutics”), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance |
|
| December 2, 2024 |
Exhibit 99.1 December 2024 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believ |
|
| December 2, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 20, 2024 |
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset Exhibit 99.1 Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset NEW YORK, November 20, 2024 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company’s Board of Directors approved the purchase of up to $1 million in Bitcoin. “As Bitcoin continues to grow, gaining investor attention and acceptance as a major |
|
| November 20, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 20, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Up to $2,700,000 Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 16, 2023) Up to $2,700,000 Common Stock Hoth Therapeutics, Inc. We have entered into an At The Market Offering Agreement dated as of November 8, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale of our common stock, par va |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Ther |
|
| November 8, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 8, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT November 8, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Hoth Therapeutics, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in thi |
|
| November 1, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hoth Therapeutics, Inc. |
|
| August 16, 2024 |
Exhibit 10.2 Appendix A AMENDMENT NO. 1 TO HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Hoth Therapeutics, Inc., a Nevada corporation (the “Company”) hereby amends its Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”) as set forth below, which amendments shall be effective as the date set forth below, but if and only if the Company’s shareholde |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeut |
|
| August 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 17, 2024 |
Amendment No. 2 to the Amended and Restated Bylaws of Hoth Therapeutics, Inc. Exhibit 3.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF HOTH THERAPEUTICS, INC. a Nevada Corporation Pursuant to resolutions of the Board of Directors (the “Board”) of Hoth Therapeutics, Inc. a Nevada corporation (the “Corporation”) adopted via unanimous written consent of the Board on June 14, 2024 and in accordance with the authority provided to the directors pursuant to Article X, Section |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| April 22, 2024 |
Hoth Therapeutics, Inc. Up to 5,030,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278620 PROSPECTUS Hoth Therapeutics, Inc. Up to 5,030,000 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 5,030,000 shares of common stock, par value $0.001 per share (the “Common Stock”) of Hoth Therapeutics, Inc. (the “Co |
|
| April 18, 2024 |
Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022 Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022 April 18, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Hoth Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278620 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act |
|
| April 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HOTH THERAPEUTICS, INC. |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission April 11, 2024 As filed with the Securities and Exchange Commission April 11, 2024 Registration Statement No. |
|
| March 28, 2024 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia merveille.ai Nevada |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 28, 2024 |
Form of Warrant Inducement Agreement Exhibit 10.36 Hoth Therapeutics, Inc. March 27, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Hoth Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per share |
|
| March 28, 2024 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 28, 2024 |
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds Exhibit 99.1 Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds NEW YORK, March 27, 2024 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of |
|
| March 28, 2024 |
Exhibit 10.1 Hoth Therapeutics, Inc. March 27, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Hoth Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per share |
|
| March 28, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 28, 2024 |
4,600,000 Shares of Common Stock Filed pursuant to rule 424(b)(3) Registration Statement No. 333-269224 Prospectus Supplement (To the Prospectus dated January 25, 2023) 4,600,000 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated January 25, 2023 (the “Original Prospectus”), relating to the offering on a resale basis of an aggregate of 4,600,000 S |
|
| March 28, 2024 |
Exhibit 97.1 HOTH THERAPEUTICS, INC. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this Cl |
|
| February 14, 2024 |
HOTH / Hoth Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth T |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 5, 2023 |
Articles of Incorporation of merveille.ai Exhibit 3.1 |
|
| September 15, 2023 |
Exhibit 99.1 Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules NEW YORK, Sept. 13, 2023 /PRNewswire/ - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equiva |
|
| September 15, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 15, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 $2.SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 13, 2023, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| September 15, 2023 |
Exhibit 99.2 Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules NEW YORK, Sept. 15, 2023 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“Hoth” or the “Company”), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq |
|
| September 15, 2023 |
Form of Placement Agent Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 15, 2023 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HOTH THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| September 14, 2023 |
Filed pursuant to Rule 424(B)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 16, 2023) 549,275 Shares of Common Stock Pre-Funded Warrants to Purchase 550,725 Shares of Common Stock (and the shares of Common Stock underlying the Pre-Funded Warrants) We are offering 549,275 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement |
|
| August 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) HOTH THERAPEUTICS, INC. |
|
| August 21, 2023 |
Exhibit 10.3 HOTH THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, yo |
|
| August 21, 2023 |
As filed with the Securities and Exchange Commission on August 21, 2023 As filed with the Securities and Exchange Commission on August 21, 2023 Registration No. |
|
| August 21, 2023 |
Exhibit 10.1 HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affil |
|
| August 21, 2023 |
Exhibit 10.2 HOTH THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, yo |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 17, 2023 |
Exhibit 99.1 |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therap |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 15, 2023 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 June 15, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-272620 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Secur |
|
| June 13, 2023 |
Exhibit 4.3 HOTH THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 S |
|
| June 13, 2023 |
Form of Subordinated Indenture Exhibit 4.4 HOTH THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certifica |
|
| June 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 13, 2023 As filed with the U.S. Securities and Exchange Commission on June 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or org |
|
| June 13, 2023 |
EX-FILING FEES 6 ea180051ex-feehoththerape.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) HOTH THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(1) Maximum Aggregate Offering Pric |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 31, 2023 |
Exhibit 10.5 These General Terms and Conditions apply to Office/Co-Working, Virtual Office and Membership agreements for services We supply to You. 1. General Agreement 1.1. Nature of an agreement: At all times, each Center remains in Our possession and control. YOU ACCEPT THAT AN AGREEMENT CREATES NO TENANCY INTEREST, LEASEHOLD ESTATE, OR OTHER REAL PROPERTY INTEREST IN YOUR FAVOR WITH RESPECT TO |
|
| March 31, 2023 |
Exhibit 10.36 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated March 28, 2023 (the “Effective Date”), is by and among Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and Robb Knie (the “Executive”). WHEREAS, the Company and Executive entered into that certain Amended and Restated Employment Agreement, dated February 20, 2019, and as amended on July 1, 2021 (t |
|
| March 31, 2023 |
Description of the Registrant’s Securities Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Hoth Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description |
|
| March 31, 2023 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
US44148G2049 / Hoth Therapeutics / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 26, 2023 |
4,600,000 Shares of Common Stock 424B3 1 ea172076-424b3hoththerap.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-269224 PROSPECTUS 4,600,000 Shares of Common Stock The selling shareholders named in this prospectus may use this prospectus to offer and resell from time to time up to 4,600,000 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 140,000 shares (the “Shares”) of ou |
|
| January 23, 2023 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 CORRESP 1 filename1.htm Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 January 23, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Arzhang Navai Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed January 13, 2023 File No. 333-269224 Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| January 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Hoth Therapeutics, Inc. |
|
| January 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 13, 2023 As filed with the U.S. Securities and Exchange Commission on January 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or |
|
| January 3, 2023 |
HOTH THERAPEUTICS, INC. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 HOTH THERAPEUTICS, INC. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 January 3, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Vanessa Robertson Kevin W. Vaughn Re: Hoth Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 30, 2022 File No. 001-38803 Dear Ladies and Gentlemen: This letter |
|
| December 30, 2022 |
Form of Placement Agent Warrants Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2022 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 30, 2022 |
Form of Registration Rights Agreement Exhibit 10.4 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL AND THE OMITTED INFORMATION IS NOT MATERIAL. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 29, 2022, between Hoth Therapeutics, Inc., |
|
| December 30, 2022 |
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, December 29, 2022/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock |
|
| December 30, 2022 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2022, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| December 30, 2022 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 13, 2022 |
Exhibit 3.1 |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| December 13, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This TRANSITION Agreement and General Release (the “AGREEMENT”) is made and entered by and between Hoth Therapeutics, Inc., including its parents, subsidiaries, and affiliates, (collectively, the “COMPANY”), on the one hand, and Stefanie Johns (“EMPLOYEE”), on the other hand (EMPLOYEE and the COMPANY are collectively referred to herein as the “ |
|
| November 14, 2022 |
DEF 14A 1 ea168522-def14ahoththerape.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for U |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| November 10, 2022 |
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements EX-99.1 2 ea168347ex99-1hoththera.htm PRESS RELEASE DATED NOVEMBER 9, 2022 Exhibit 99.1 Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements NEW YORK, November 9, 2022 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, i |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment (this ?Amendment?) to the Employment Agreement is dated as of November 10, 2022, and effective this same date, and is entered into by and between Hoth Therapeutics, Inc., a Nevada corporation (the ?Corporation?), and Stefanie Johns (the ?Employee?). All capitalized terms used herein but not otherwise defined shall have the m |
|
| November 3, 2022 |
Exhibit 3.1 HOTH THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK The following recital and resolution was duly adopted by the board of directors (the “Board of Directors”) of Hoth Therapeutics, Inc., a Nevada corporation (the “Corporation”), in accordance with the provisions of Nevada Revised Statutes (“NRS”) 78.1955: WHEREAS, the articles of incorporation of the Corporat |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 3, 2022 |
Subscription and Investment Representation Agreement dated November 2, 2022 Exhibit 10.1 It is the responsibility of any investor purchasing these securities to satisfy itself as to full observance of the laws of any relevant territory outside the United States in connection with any such purchase, including obtaining any required governmental or other consents or observing any other applicable requirements. We are not making an offer to sell these securities in any juris |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 20, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| October 24, 2022 |
Exhibit 99.1 Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 NEW YORK, NY October 24, 2022 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern |
|
| October 24, 2022 |
Exhibit 3.1 |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 22, 2022 |
Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF HOTH THERAPEUTICS, INC. a Nevada Corporation Pursuant to resolutions of the Board of Directors (the ?Board?) of Hoth Therapeutics, Inc. a Nevada corporation (the ?Corporation?) adopted at a meeting of the Board held on August 19, 2022 and in accordance with the authority provided to the directors pursuant to Article X, Section 10.1 of t |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| July 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2022 |
Exhibit 99.1 |
|
| July 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 ?Registration No. |
|
| July 1, 2022 |
EX-FILING FEES 4 ea162151ex-feehoththerape.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) HOTH THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit M |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 13, 2022 |
Exhibit 99.1 |
|
| June 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| April 29, 2022 |
Exhibit 99.1 Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs APRIL 2022 Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ?could,? ?believe,? ?a |
|
| April 29, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 11, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 13, 2022 |
424B5 1 ea158364-424b5hoththerape.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(B)(5) Registration No. 333-236887 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 11, 2020) 8,235,294 Shares Common Stock We are offering 8,235,294 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on The N |
|
| April 13, 2022 |
Exhibit 99.2 Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market NEW YORK, NY April 11, 2022/ PR Newswire / Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the ?Common Stock?) at a public offering price of |
|
| April 13, 2022 |
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock NEW YORK, April 11, 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The propose |
|
| April 13, 2022 |
Exhibit 1.1 8,235,294 SHARES of Common Stock Hoth Therapeutics, Inc. UNDERWRITING AGREEMENT April 11, 2022 EF Hutton, division of Benchmark Investments, LLC As Representative of the Several Underwriters named on Schedule I attached hereto 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Hoth Therapeutics, Inc., a company incorporated under the laws of |
|
| April 11, 2022 |
SUBJECT TO COMPLETION DATED APRIL 11, 2022 Filed pursuant to Rule 424(B)(5) Registration No. 333-236887 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| April 4, 2022 |
PRE 14A 1 ea157893-pre14ahoththerape.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for |
|
| March 30, 2022 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 30, 2022 |
Description of the Registrant’s Securities Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Hoth Therapeutics, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description |
|
| February 23, 2022 |
HOTH / Hoth Therapeutics Inc / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date o |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 9, 2022 |
HOTH / Hoth Therapeutics Inc / Lind Global Macro Fund LP Passive Investment SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) HOTH THERAPEUTICS, INC. |
|
| February 4, 2022 |
Exhibit 10.1 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN EFFECTIVE AS OF MAY 4, 2018 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN EFFECTIVE AS OF MAY 4, 2018 SECTION 1. INTRODUCTION. The Company?s Board of Directors adopted the Hoth Therapeutics, Inc. 2018 Equity Incentive Plan effective as of the Adoption Date subject to obtaining Company shareholder approval as provided in Section 1 |
|
| February 4, 2022 |
As filed with the Securities and Exchange Commission on February 4, 2022 As filed with the Securities and Exchange Commission on February 4, 2022 ?Registration No. |
|
| February 3, 2022 |
HOTH / Hoth Therapeutics Inc / Ionic Ventures, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44148G 10 5 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 4, 2022 |
EX-99.1 2 ea153383ex99-1hoththerap.htm PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED JANUARY 4, 2022 Exhibit 99.1 Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer’s Disease Significant decrease in Aβ seen in an Alzheimer’s disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ has the potential to modify Aβ plaque formati |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| December 8, 2021 |
Exhibit 99.1 Hoth Therapeutics Licenses Lupus Therapeutic Back to Zyl? Therapeutics Hoth to receive shares in Zyl? and potential future sales royalties NEW YORK, NY December 8, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into a |
|
| December 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| September 1, 2021 |
EX-99.1 2 ea146814ex99-1hoththera.htm PRESENTATION MATERIALS Exhibit 99.1 Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs SEPTEMBER 2021 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These s |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| June 30, 2021 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Employment Agreement dated as of June 25, 2021, and effective as of July 1, 2021, is entered into between by and between Hoth Therapeutics, a Nevada corporation (the ?Company?), and Jane H. Springer (the ?Employee?). All capitalized terms used herein but not otherwise defined sh |
|
| June 30, 2021 |
Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (this ?Amendment?) to the Employment Agreement is dated as of June 25, 2021, and effective as of July 1, 2021, and is entered into by and between Hoth Therapeutics, Inc., a Nevada corporation (the ?Corporation?), and Stefanie Johns (the ?Employee?). All capitalized terms used herein but not otherwise defined shall have the |
|
| June 30, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Amended and Restated Employment Agreement dated as of June 25, 2021, and effective as of July 1, 2021, is entered into between by and between Hoth Therapeutics, a Nevada corporation (the ?Corporation?), and Robb Knie (the ?Executive?). All capitalized terms used herein but not o |
|
| June 30, 2021 |
Exhibit 99.1 Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis The primary objectives were achieved in cohort one BioLexa was well-tolerated with no treatment related adverse events Initiating Cohort 2 patient screening in September NEW YORK, NY June 28, 2021/ PR Newswire/ Today, Hoth Therapeutics, I |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2021 |
Exhibit 99.1 Introduction to HT - KIT an mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell - Derived Cancers Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ?could,? ?believe |
|
| May 24, 2021 |
Exhibit 99.2 m o c . s c NASDAQ: HOTH i t u e ap r e h t h t o h www. 1 Introduction to HT - 001 Topical Gel www.hoththerapeutics.com N A S D A Q: HOTH 2 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ? |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 7, 2021 |
- DEFINITIVE REVISED PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 12, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 6, 2021 |
15,569,621 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-254638 PROSPECTUS 15,569,621 Shares of Common Stock The selling shareholders named in this prospectus may use this prospectus to offer and resell from time to time up to 15,569,621 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 6,826,962 shares (the “Shares”) of our common stock issued in a private placement |
|
| March 30, 2021 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 March 30, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed March 23, 2021 File No. 333-254638 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regul |
|
| March 23, 2021 |
As filed with the U.S. Securities and Exchange Commission on March 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or or |
|
| March 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44148G105 (CUSIP Number) March 10, 2021 (Date of Ev |
|
| March 16, 2021 |
Description of the Registrant’s Securities Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Hoth Therapeutics, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 16, 2021 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia |
|
| March 9, 2021 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of March 8, 2021, between Hoth Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase |
|
| March 9, 2021 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 8, 2021, between Hoth Therapeutics, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| March 9, 2021 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 9, 2021 |
Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, March 8, 2021/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain institutional and accredited investors for the issuance and sale of an agg |
|
| March 9, 2021 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 9, 2021 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 HOTH THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 44148G105 (CUSIP Number) May 26, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 29, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”) to the Employment Agreement is dated as of January 29, 2021 and effective as of February 1, 2021 and is entered into by and between Hoth Therapeutics, Inc., a Nevada corporation (the “Corporation”) and Stefanie Johns (the “Employee”). All capitalized terms used herein but not otherwise defined shall have th |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 25, 2021 |
Exhibit 99.1 |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) January 8, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 25, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Hoth Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. January 25, 2021 LIND GLOBAL MACRO FUND, LP By: Lind Global Partners |
|
| January 25, 2021 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 19, 2021 |
3,712,872 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) File No. 333-251994 3,712,872 Shares of Common Stock This prospectus relates to the sale from time to time of up to 3,712,872 shares of common stock held by the selling stockholders named in this prospectus, including 2,475,248 outstanding shares of common stock and 1,237,624 shares of common stock issuable upon exercise of outstanding warrants (“Warrant |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) January 7, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 13, 2021 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 January 13, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed January 8, 2021 File No. 333-251994 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Re |
|
| January 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 par value (Title of Class of Securities) 44148G 10 5 (CUSIP Number) January 7, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 8, 2021 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 8, 2021 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 8, 2021 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 5, 2021, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| January 8, 2021 |
Exhibit 99.2 Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules Definitive Agreement for $5.0 Million in Gross Proceeds NEW YORK, NY January 5, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement t |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 8, 2021 |
Exhibit 99.1 Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections License Covers Novel Molecular Entity Developed by the Walter Reed Army Institute of Research The HT-006 active pharmaceutical ingredient is expected to be a broad-spectrum antibiotic for treatme |
|
| January 8, 2021 |
As filed with the U.S. Securities and Exchange Commission on January 8, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or o |
|
| January 8, 2021 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 5, 2021, between Hoth Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purcha |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| September 21, 2020 |
Exhibit 10.1 SPONSORED RESEARCH AGREEMENT between HOTH THERAPEUTICS, INC. and THE GEORGE WASHINGTON UNIVERSITY This sponsored research agreement (“Agreement”), effective as of September 1, 2020 (“Effective Date”), is entered into by and between Hoth Therapeutics, Inc., a State of Nevada corporation, having offices at One Rockefeller Plaza Suite 1039, New York, NY 10020 (“Sponsor”) and the George W |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 17, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| September 21, 2020 |
HOTH THERAPEUTICS ENTERS INTO SPONSORED RESEARCH AGREEMENT FOR ON-THE-GO COVID-19 TESTING DEVICE Exhibit 99.1 HOTH THERAPEUTICS ENTERS INTO SPONSORED RESEARCH AGREEMENT FOR ON-THE-GO COVID-19 TESTING DEVICE Company will Partner with the George Washington University on R&D for their Licensed Smartphone-Based Direct Virus Sensing System NEW YORK , Sept. 21, 2020 /PRNewswire/ - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsor |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 10, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| August 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 31, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into as of this 28th day of August, 2020 and will go effective as of September 8, 2020 (the “Effective Date”), by and between HOTH THERAPEUTICS INC, a Nevada corporation (the “Corporation”), and Stefanie Johns (the “Employee”), under the following circumstances: RECITALS: A. The Corporation desires to secure the servic |
|
| August 31, 2020 |
Hoth Therapeutics Appoints Dr. Stefanie Johns, Ph.D., as Chief Scientific Officer Exhibit 99.1 Hoth Therapeutics Appoints Dr. Stefanie Johns, Ph.D., as Chief Scientific Officer NEW YORK, NY August 31, 2020 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020. In her role, Dr. Johns will further advance Hoth’s pipeline throug |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 13, 2020 |
Exhibit 10.9 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. The George Washington University Patent License Agreement This Patent License Agreement (this “Agreement”) is between the George Washington University, a congressionally chartered not-for-profit corporation (“Uni |
|
| August 13, 2020 |
Exhibit 10.5 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Second Amendment to Exclusive License Agreement This second Amendment to the Exclusive License Agreement effective as of February 27, 2013 is effective as of January 2, 2018 and is by and between the University o |
|
| August 13, 2020 |
Exhibit 10.4 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This first Amendment to the Exclusive License Agreement effective as of February 27, 2013 is effective as of April 17, 2013 and is by and between the University of C |
|
| August 13, 2020 |
Exhibit 10.6 ASSIGNMENT AND ASSUMPTION AGREEMENT This Assignment and Assumption Agreement (the “Agreement”), is effective as of the 14th day of May, 2020 (the “Effective Date”) between Chelexa BioSciences, Inc., having an address at 181 Market Street, Unit 20, Lowell, MA 01852 (the “Assignor”) and Hoth Therapeutics, Inc., having an address at 1 Rockefeller Plaza, Suite 1039, New York, New York 100 |
|
| August 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| August 13, 2020 |
Exhibit 10.8 Novation Agreement This Novation, dated as of the Effective Date, is entered into by and among Chelexa BioSciences, Inc., having an address at 181 Market Street, Unit 20, Lowell, MA 01852 (the “Assignor”) and Hoth Therapeutics, Inc., having an address at 1 Rockefeller Plaza, Suite 1039, New York, New York 10020 (the “Assignee”), and The University of Cincinnati, a state institution of |
|
| August 13, 2020 |
Exhibit 10.7 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ROYALTY AGREEMENT This Royalty Agreement (this “Agreement”) is effective as of the 14th day of May, 2020 (the “Effective Date”) by and between Chelexa BioSciences, Inc., having an address at 181 Market Street, Un |
|
| August 13, 2020 |
Exhibit 10.3 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. License Agreement THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is effective as of February 27, 2013 (the “Effective Date”), and is by and between the University of Cincinnati, a state institution of higher |
|
| August 10, 2020 |
Exhibit 99.1 Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device Project Originally Funded at George Washington University by COVID-19 Technology Maturation Grant No Saliva or Blood Needed Potential to Allow Public Health Professionals to Immediately Diagnose COVID-19 Infection Via Breath Sample and Track Through A Mobile Device NEW YO |
|
| August 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2020 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 5, 2020 |
Exhibit 99.1 Hoth Therapeutics’ Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases Hoth to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields including Oncology NEW YORK, NY July 31, 2020 - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement |
